Biocon Limited — Updates, 24-02-2025: Press Release

Biocon Biologics Ltd. (BBL) has successfully launched YESINTEK™ (ustekinumab-kfce), a biosimilar to Stelara®, in the United States, enhancing access to cost-effective treatment options for patients with chronic autoimmune diseases like Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. YESINTEK is available in multiple formulations and is notable as one of the first biosimilar entrants in the U.S. market.

CEO Shreehas Tambe emphasized this launch as a pivotal moment in Biocon's commitment to patient health and a significant step since the company became a fully integrated global biosimilars entity. YESINTEK has commercial payor coverage at launch, complemented by a robust patient assistance program to help reduce out-of-pocket costs.

The introduction of YESINTEK reflects Biocon's strategic focus on expanding its portfolio in key markets, positioning the company for potential growth amid increasing patient demand for alternative treatment options in immunology. Investors should view this development positively as it aligns with Biocon’s long-term goals of enhancing patient access to high-quality biosimilars.